Mziwandile Madikizela

affiliation not provided to SSRN

SCHOLARLY PAPERS

2

DOWNLOADS

242

SSRN CITATIONS

0

CROSSREF CITATIONS

0

Scholarly Papers (2)

Actions:
Email selected abstracts
1.

Investing in Late-Stage Clinical Trials and Manufacturing of Neglected Disease Product Candidates – Modeling the Benefits and Costs of Investments for Three Middle-Income Countries

Number of pages: 92 Posted: 13 Aug 2021
Marco Schäferhoff, Armand Zimmerman, Mohamed Mustafa Diab, Wenhui Mao, Vipul Chowdhary, Davinder Gill, Robert Karanja, Mziwandile Madikizela, Osondu Ogbuoji and Gavin Yamey
Open Consultants, Duke University - Duke Global Health Institute, Center for Policy Impact in Global Health, Duke University - Duke Global Health Institute, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Duke University and Duke Global Health Institute
Downloads 122 (344,023)

Abstract:

Loading...

2.

Developing an Aggregator Mechanism for Late-Stage Clinical Trials of Neglected Disease Product Candidates

Duke Global Working Paper Series No. 23
Number of pages: 98 Posted: 21 Oct 2020
Gavin Yamey, Marco Schäferhoff, Mary Moran, Mohamed Mustafa Diab, Kaci Kennedy McDade, Wenhui Mao, Parth Chodavadia, Armand Zimmerman, Vipul Chowdhary, Robert Karanja, Mziwandile Madikizela and Osondu Ogbuoji
Duke Global Health Institute, Open Consultants, Duke University, Center for International and Global Studies, Center for Policy Impact in Global Health, Center for Policy Impact in Global Health, Duke University, Duke University - Duke Global Health Institute, Duke Global Health Institute, Duke University - Duke Global Health Institute, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN and Duke University
Downloads 120 (348,140)
Citation 1

Abstract:

Loading...

poverty-related and neglected diseases (PRNDs), aggregator mechanism, research and development, clinical trials, antimicrobial resistance, infectious diseases, Covid-19, AIDS, tuberculosis, malaria, public funding for R&D, vaccine, public health